New combo aims to make inoperable lung cancer operable

NCT ID NCT06449313

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether giving chemotherapy plus the immunotherapy drug cemiplimab (Libtayo) before surgery can shrink tumors enough to allow surgical removal in people with stage 3 non-small cell lung cancer that has spread to certain lymph nodes (N3). About 21 participants will receive four cycles of the drug combination, then undergo surgery if the tumor shrinks. After surgery, they may receive radiation and continue cemiplimab for a year. The main goal is to see how many patients have no cancer cells left in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cemiplimab (Libtayo) plus platinum-doublet chemotherapy
What this could lead to: If successful, this approach could allow more patients with advanced lung cancer to have surgery and potentially improve long-term control of the disease.
What could go wrong: This is a small, early-phase trial with only 21 participants, so results may not apply broadly. The combination of chemo and immunotherapy can cause significant side effects, and not all tumors will shrink enough for surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER STAGE III

Contacts and locations

Locations

Lombardi Comprehensive Cancer Center, Georgetown University
RECRUITING

Washington D.C., District of Columbia, 20007, United States
UVA Comprehensive Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States
Washington University School of Medicine-Sitemen Cancer Center
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.